IHA Founder: Prof. M. Togha

Headache disorders, which affect the majority of people, are the most frequent brain conditions among the general population. The IHA (Iranian Headache Association), a national nonprofit organization supervised by the Iranian neurological association, has sought to improve the lives of those affected by headache in Iran. The IHA dedicates its efforts to the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Focus is upon teaching key players, such as neurologists, general practitioners and all those involved in headache management, about the diagnosis and treatment of headache disorders. We thank you for your interest in the IHA! Please be sure to visit the many sections of our website to learn more about headache and find out how you can be a part of our important mission of improving lives today.

 

Last News

10Jul

Joint Meeting of 1st Iranian Headache School and 6th European Headache Federation School of Advanced Studies

The Iranian Headache Association in collaboration with the European Headache Federation will hold a “Headache School” for neurologists and general practitioners in Tehran, Islamic Republic of Iran Time schedule Oct, 4-6, 2018.  Read More →
10Jul

REVIEW ARTICLE cGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine

Kasra Maasumi1•Rebecca L. Michael1•Alan M. Rapoport Key Points Migraine is a chronic, disabling neurological disease with high unmet clinical needs. Calcitonin gene-related peptide (CGRP) is a promising therapeutic target for the treatment of migraine. Numerous trials investigating CGRP receptor antagonists, anti-CG RP antibodies and anti-CGRP receptor antibodies have been completed and demonstrate efficacy in migraine within a short period of time. Thus far, these agents have been demonstrated t  Read More →
12Jun

Migraine is first cause of disability in under 50s: will health politicians now take notice?

Migraine is first cause of disability in under 50s: will health politicians now take notice? Timothy J. Steiner,corresponding author, Lars J. Stovner, Theo Vos, R. Jensen, and Z. Katsarava  Read More →
29May

Novartis and Amgen announce FDA approval of Aimovig™ (erenumab), a novel treatment developed specifically for migraine prevention

Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States • Aimovig is the first and only FDA-approved treatment to block the calcitonin generelated peptide receptor (CGRP-R), which plays an important role in migraine • Aimovig was consistently shown to reduce monthly migraine days, including in more difficult to treat populations, with many patients achieving at least a 50% reduction  Read More →
22May

The 4th EHF School of Advanced Studies

The 4th EHF School of Advanced Studies will be held in Rome, 22-24 June 2018. 20 Full-bursaries available. Programme and application:   Read More →
02May

25th Congress of Neurology & Clinical Electrophysiology Of Iran

May 1-4 , 2018 (11-14 Ordibehesht 1397) Olympic Hotel, Tehran, Iran  Read More →
25Apr

IHS Newsletter - March 2018

IHS Newsletter Issue 19 -- March 2018 Welcome to the 19th edition of the IHS Newsletter, our in-house online publication to update you on key IHS and related society activities. Please click here to visit the Newsletter section of the IHS website where you can view and download Issue 19 of the IHS Newsletter.   Read More →
03Apr

IASP Collaborative Research Grants

April 4 Deadline Pending for 2018 IASP Collaborative Research Grant Submissions  Read More →
28Feb

Master of Headache Disorders 2018 - Intake is now open

Master of Headache Disorders 2018 - Intake is now open http://mhd.ku.dk/  Read More →
27Jan

"Frontiers in Headache Research" Scholarship applications

New Scholarship Opportunities The American Headache Society announces the availability of up to 10  "Frontiers in Headache Research" Scholarship Awards for the 60th Annual Scientific Meeting, June 28-July 1, 2018 at the Marriott Marquis San Francisco.  Read More →

Upcoming Event

Back to Top